MA27885A1 - Derives de n-pyrrolidine-3-ylamide servant d'inhibiteurs de reabsorption de serotonine et de noradrenaline - Google Patents
Derives de n-pyrrolidine-3-ylamide servant d'inhibiteurs de reabsorption de serotonine et de noradrenalineInfo
- Publication number
- MA27885A1 MA27885A1 MA28674A MA28674A MA27885A1 MA 27885 A1 MA27885 A1 MA 27885A1 MA 28674 A MA28674 A MA 28674A MA 28674 A MA28674 A MA 28674A MA 27885 A1 MA27885 A1 MA 27885A1
- Authority
- MA
- Morocco
- Prior art keywords
- alkyl
- aryl
- het
- alkoxy
- serotonin
- Prior art date
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title abstract 6
- 229940076279 serotonin Drugs 0.000 title abstract 3
- NGXSWUFDCSEIOO-UHFFFAOYSA-N pyrrolidin-3-amine Chemical class NC1CCNC1 NGXSWUFDCSEIOO-UHFFFAOYSA-N 0.000 title abstract 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229960002748 norepinephrine Drugs 0.000 title 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 abstract 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- -1 SCF3 Chemical group 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
DEPOSANT Société dite : PFIZER INC. REVENDICATION DE PRIORITES GB 17 Juin 2003 GB 0314048.0 US 6 Août 2003 60/493,126 Dérivés de N-pyrrolidine-3-ylamide servant d'inhibiteurs de réabsorption de sérotonine et de noradrénaline Un composé de formule (I) et ses dérivés acceptables du point de vue pharmaceutique et/ou vétérinaire, formule dans laquelle R1 représente H, un groupe alkyle en C1 à C6, -C(X)Y, cycloalkyle en C3 à C8, aryle, het, aryl (alkyle en C1 à C4) ou het (alkyle en C1 à C4) , dans lequel les groupes cycloalkyle, aryle ou het sont facultativement substitués avec au moins un substituant choisi indépendamment entre des substituants alkyle en C1 à C8, alkoxy en C1 à C8, OH, halogéno, CF3, OCF3, SCF3, hydroxyalkyle en C1 à C6, (alkoxy en C1 à C4) (alkyle en C1 à C6) et (alkyle en C1 à C4) S (alkyle en C1 à C4) , R2 représente un groupe aryle ou hétéroaryle, chacun facultativement substitué avec au moins un substituant choisi indépendamment entre des substituants alkyle en C1 à C8, alkoxy en C1 à C8, OH, halogéno, CF3, OCF3, SCF3, hydroxyalkyle en C1 à C6, (alkoxy en C1 à C4) (alkyle en C1 à C6) et (alkyle en C1 à C4) S (alkyle en C1 à C4) ; R3 représente un groupe alkyle en C1 à C6, cycloalkyle en C3 à C8, (cycloalkyle en C3 à C8) (alkyle en C1 à C6) , aryle, het, aryl (alkyle en C8 à C4) ou het (alkyle en C1 à C4) , dans lequel les groupes cycloalkyle, aryle ou het sont facultativement substitués avec au moins un substituant choisi indépendamment entre des substituants alkyle en C1 à C6, alkoxy en C1 à C6, OH, halogéno, CF3, OCF3, SCF3, hydroxyalkyle en C1 à C6, (alkoxy en C1 à C6) (alkyle en C1 à C6) et (alkyle en C1 à C4) S (alkyle en C1 à C4) ; X représente S ou O ; Y représente H, un groupe alkyle en C1 à C6, aryle, het, aryl (alkyle en C1 à C4) ou het (alkyle en C1 à C4) ; et n est égal à 1 ou 2 ; sous réserve que, lorsque n est égal à 1, m est égal à 0 ou 1 et, lorsque n est égal à 2, m est égal à 0, oé, si m est égal à 0, alors * représente un centre chiral. Les composés de la présente invention ont une activité comme inhibiteurs de réabsorption de sérotonine et de noradrénaline et, en conséquence, sont utiles dans divers domaines thérapeutiques, par exemple l'incontinence urinaire.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0314048.0A GB0314048D0 (en) | 2003-06-17 | 2003-06-17 | Novel compounds |
| US49312603P | 2003-08-06 | 2003-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27885A1 true MA27885A1 (fr) | 2006-05-02 |
Family
ID=33554153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28674A MA27885A1 (fr) | 2003-06-17 | 2005-12-16 | Derives de n-pyrrolidine-3-ylamide servant d'inhibiteurs de reabsorption de serotonine et de noradrenaline |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US7378436B2 (fr) |
| EP (1) | EP1638933B1 (fr) |
| JP (1) | JP4137159B2 (fr) |
| KR (1) | KR100803796B1 (fr) |
| AP (1) | AP2005003467A0 (fr) |
| AR (1) | AR044715A1 (fr) |
| AT (1) | ATE398107T1 (fr) |
| AU (1) | AU2004247487B2 (fr) |
| BR (1) | BRPI0411594A (fr) |
| CA (1) | CA2530159C (fr) |
| CY (1) | CY1110434T1 (fr) |
| DE (1) | DE602004014372D1 (fr) |
| DK (1) | DK1638933T3 (fr) |
| EA (1) | EA009881B1 (fr) |
| EC (1) | ECSP056232A (fr) |
| ES (1) | ES2305776T3 (fr) |
| HR (2) | HRP20050993A2 (fr) |
| IL (1) | IL172063A0 (fr) |
| IS (1) | IS8136A (fr) |
| MA (1) | MA27885A1 (fr) |
| MX (1) | MXPA05013960A (fr) |
| NL (1) | NL1026438C2 (fr) |
| NZ (1) | NZ544046A (fr) |
| PA (1) | PA8605301A1 (fr) |
| PE (1) | PE20050631A1 (fr) |
| PL (1) | PL1638933T3 (fr) |
| PT (1) | PT1638933E (fr) |
| SI (1) | SI1638933T1 (fr) |
| TW (1) | TW200505852A (fr) |
| UY (1) | UY28360A1 (fr) |
| WO (1) | WO2004110995A1 (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60133203T3 (de) * | 2000-07-31 | 2012-02-23 | Nycomed Danmark Aps | Fentanyl Zusammensetzung für nasale Anwendung |
| ES2305776T3 (es) * | 2003-06-17 | 2008-11-01 | Pfizer Inc. | Derivados de n-pirrolidin-3-il-amida como inhibidores de la re-captacion de serotonina y noradrenalina. |
| WO2006044454A1 (fr) | 2004-10-18 | 2006-04-27 | Eli Lilly And Company | Derives de 1-(hetero)aryl-3-amino-pyrollidine utiles comme antagonistes des recepteurs mglur3 |
| GB0425766D0 (en) * | 2004-11-23 | 2004-12-22 | Pfizer Ltd | Novel compounds |
| US7122683B2 (en) | 2004-11-23 | 2006-10-17 | Pfizer Inc. | Amides useful as monoamine re-uptake inhibitors |
| US20090239928A1 (en) * | 2004-12-14 | 2009-09-24 | Paul Vincent Fish | N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors |
| JP2008523136A (ja) * | 2004-12-14 | 2008-07-03 | ファイザー・リミテッド | セロトニンおよびノルアドレナリン再取り込み阻害剤としてのｎ−ピロリジン−３−イル−アミド誘導体 |
| TWI410406B (zh) * | 2005-05-13 | 2013-10-01 | Otsuka Pharma Co Ltd | 吡咯烷化合物 |
| EP1893603B1 (fr) * | 2005-06-02 | 2009-10-14 | F. Hoffmann-La Roche AG | Derives de la piperidin-4-yl-amide et leur utilisation comme antagonistes du sous type 5 du recepteur sst |
| WO2007135530A2 (fr) * | 2006-05-22 | 2007-11-29 | Pfizer Limited | Sel adapté à un usage pharmaceutique et vétérinaire |
| US20080014152A1 (en) * | 2006-07-13 | 2008-01-17 | Di Mauro Thomas M | Intranasal delivery of clenbuterol across the cribriform plate and into the brain |
| JP5219465B2 (ja) * | 2006-11-10 | 2013-06-26 | 大塚製薬株式会社 | 医薬 |
| US20100056497A1 (en) * | 2007-01-31 | 2010-03-04 | Dainippon Sumitomo Pharma Co., Ltd | Amide derivative |
| JP2010189275A (ja) * | 2007-06-14 | 2010-09-02 | Dainippon Sumitomo Pharma Co Ltd | ナフタレン誘導体 |
| US8263652B2 (en) | 2007-10-31 | 2012-09-11 | Sk Biopharmaceuticals Co., Ltd. | Stabilized pediatric suspension of carisbamate |
| AU2008339351B2 (en) * | 2007-12-19 | 2013-02-28 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic heterocyclic derivative |
| JP5405571B2 (ja) | 2008-07-24 | 2014-02-05 | セラヴァンス， インコーポレーテッド | ３−（フェノキシフェニルメチル）ピロリジン化合物 |
| SI2358675T1 (sl) | 2008-11-14 | 2013-01-31 | Theravance, Inc. | 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine |
| US20100267743A1 (en) * | 2009-04-15 | 2010-10-21 | Stangeland Eric L | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
| JP5331883B2 (ja) | 2009-06-24 | 2013-10-30 | 大日本住友製薬株式会社 | Ｎ−置換−環状アミノ誘導体 |
| CN102471258A (zh) * | 2009-07-13 | 2012-05-23 | 施万制药 | 3-苯氧基甲基吡咯烷化合物 |
| JP5714580B2 (ja) | 2009-07-21 | 2015-05-07 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ３−フェノキシメチルピロリジン化合物 |
| WO2011085291A1 (fr) | 2010-01-11 | 2011-07-14 | Theravance, Inc. | Composés de type 1-(2-phénoxyméthylphényl)pipérazine comme inhibiteurs du recaptage de la sérotonine et de la norépinéphrine |
| EP2550252B1 (fr) * | 2010-03-22 | 2015-05-06 | Theravance Biopharma R&D IP, LLC | Composés de 1-(2-phénoxyméthylhétéroaryl)pipéridine et pipérazine |
| WO2012051103A1 (fr) | 2010-10-11 | 2012-04-19 | Theravance, Inc. | Inhibiteurs de la réabsorption de sérotonine |
| WO2012075239A1 (fr) | 2010-12-03 | 2012-06-07 | Theravance, Inc. | Inhibiteurs de la recapture de la sérotonine |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE138773C (fr) | ||||
| US3963745A (en) | 1972-04-03 | 1976-06-15 | A. H. Robins Company, Incorporated | Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides |
| US4002757A (en) * | 1974-12-26 | 1977-01-11 | A. H. Robins Company, Incorporated | N-(1-substituted-3-pyrrolidinyl)-4-quinolinecarboxamides |
| US4020072A (en) | 1976-05-04 | 1977-04-26 | E. R. Squibb & Sons, Inc. | 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines |
| GB1574419A (en) * | 1977-11-11 | 1980-09-03 | Anphar Sa | Piperidine compounds |
| CH628885A5 (en) * | 1978-01-01 | 1982-03-31 | Anphar Sa | Piperidine derivative |
| US5130312A (en) * | 1987-07-17 | 1992-07-14 | Janssen Pharmaceutica N.V. | Substituted N-(3-hydroxy-4-piperidinyl)benzamides |
| FR2642069B1 (fr) | 1989-01-20 | 1991-04-12 | Rhone Poulenc Sante | Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent |
| JP2000500502A (ja) | 1995-11-22 | 2000-01-18 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質トランスフェラーゼ阻害剤 |
| AU4167099A (en) | 1998-06-19 | 2000-01-05 | Nissan Chemical Industries Ltd. | Heterocyclic compounds as hypoglycemic agents |
| US6670299B1 (en) * | 1999-07-03 | 2003-12-30 | Northwestern University | Cyclopentadienyl-containing low-valent early transition metal olefin polymerization catalysts |
| FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| WO2001066114A1 (fr) | 2000-03-03 | 2001-09-13 | Eisai Co., Ltd. | Nouvelles methodes reposant sur l'utilisation d'inhibiteurs de cholinesterase |
| EP1263729B1 (fr) * | 2000-03-06 | 2006-12-20 | Acadia Pharmaceuticals Inc. | Composes azacycliques utilises dans le traitement de maladies liees a la serotonine |
| WO2002024694A1 (fr) | 2000-09-22 | 2002-03-28 | Smithkline Beecham, P.L.C. | Pyrazolopyridines et pyrazolopyridazines utilisees comme antidiabetiques |
| AU2001291830A1 (en) | 2000-09-25 | 2002-04-02 | Actelion Pharmaceuticals Ltd. | Substituted amino-aza-cycloalkanes useful against malaria |
| EP1430027B1 (fr) | 2001-09-14 | 2010-09-01 | High Point Pharmaceuticals, LLC | Nouveau derives d'aminoazetidine, d'aminopyrrolidine et d'aminopiperidine |
| CA2468761A1 (fr) | 2001-10-31 | 2003-05-08 | Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie | Nouveaux composes anticancereux |
| GB0128287D0 (en) | 2001-11-26 | 2002-01-16 | Smithkline Beecham Plc | Novel method and compounds |
| KR20050008846A (ko) * | 2002-06-24 | 2005-01-21 | 아카디아 파마슈티칼스 인코포레이티드 | 세로토닌 수용체 제제로서의 ｎ-치환된 피페리딘 유도체 |
| AU2003249983A1 (en) | 2002-07-18 | 2004-02-09 | Actelion Pharmaceuticals Ltd | Piperidines useful for the treatment of central nervous system disorders |
| AU2003263393A1 (en) | 2002-09-04 | 2004-03-29 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| MXPA05006507A (es) | 2002-12-20 | 2006-02-17 | Chemocentryx | Inhibidores de ccxckr2 expresado en tumor humano. |
| ES2305776T3 (es) * | 2003-06-17 | 2008-11-01 | Pfizer Inc. | Derivados de n-pirrolidin-3-il-amida como inhibidores de la re-captacion de serotonina y noradrenalina. |
-
2004
- 2004-06-07 ES ES04736241T patent/ES2305776T3/es not_active Expired - Lifetime
- 2004-06-07 NZ NZ544046A patent/NZ544046A/en unknown
- 2004-06-07 CA CA002530159A patent/CA2530159C/fr not_active Expired - Fee Related
- 2004-06-07 WO PCT/IB2004/001943 patent/WO2004110995A1/fr not_active Ceased
- 2004-06-07 AU AU2004247487A patent/AU2004247487B2/en not_active Expired - Fee Related
- 2004-06-07 SI SI200430767T patent/SI1638933T1/sl unknown
- 2004-06-07 EP EP04736241A patent/EP1638933B1/fr not_active Expired - Lifetime
- 2004-06-07 PT PT04736241T patent/PT1638933E/pt unknown
- 2004-06-07 MX MXPA05013960A patent/MXPA05013960A/es active IP Right Grant
- 2004-06-07 JP JP2006516540A patent/JP4137159B2/ja not_active Expired - Fee Related
- 2004-06-07 BR BRPI0411594-5A patent/BRPI0411594A/pt not_active IP Right Cessation
- 2004-06-07 DE DE602004014372T patent/DE602004014372D1/de not_active Expired - Lifetime
- 2004-06-07 AP AP2005003467A patent/AP2005003467A0/xx unknown
- 2004-06-07 PL PL04736241T patent/PL1638933T3/pl unknown
- 2004-06-07 AT AT04736241T patent/ATE398107T1/de not_active IP Right Cessation
- 2004-06-07 DK DK04736241T patent/DK1638933T3/da active
- 2004-06-07 EA EA200501730A patent/EA009881B1/ru not_active IP Right Cessation
- 2004-06-07 KR KR1020057024147A patent/KR100803796B1/ko not_active Expired - Fee Related
- 2004-06-07 HR HR20050993A patent/HRP20050993A2/hr not_active Application Discontinuation
- 2004-06-07 HR HR20080339T patent/HRP20080339T3/xx unknown
- 2004-06-14 UY UY28360A patent/UY28360A1/es not_active Application Discontinuation
- 2004-06-14 PE PE2004000590A patent/PE20050631A1/es not_active Application Discontinuation
- 2004-06-16 PA PA20048605301A patent/PA8605301A1/es unknown
- 2004-06-16 AR ARP040102082A patent/AR044715A1/es not_active Application Discontinuation
- 2004-06-16 TW TW093117317A patent/TW200505852A/zh unknown
- 2004-06-17 US US10/872,160 patent/US7378436B2/en not_active Expired - Fee Related
- 2004-06-17 NL NL1026438A patent/NL1026438C2/nl not_active IP Right Cessation
-
2005
- 2005-11-20 IL IL172063A patent/IL172063A0/en unknown
- 2005-11-21 IS IS8136A patent/IS8136A/is unknown
- 2005-12-16 EC EC2005006232A patent/ECSP056232A/es unknown
- 2005-12-16 MA MA28674A patent/MA27885A1/fr unknown
-
2008
- 2008-05-21 US US12/124,755 patent/US20080306123A1/en not_active Abandoned
- 2008-08-14 CY CY20081100869T patent/CY1110434T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2328486C2 (ru) | Производные 2-пиридона в качестве ингибиторов нейтрофильной эластазы | |
| MA32164B1 (fr) | Derive heterocyclique fusionne et son utilisation | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| WO2003080580A3 (fr) | Composes | |
| DK0794949T3 (da) | Hidtil ukendte 3,5-dioxo-(2H,4H)-1,2,4-triazinderivater, fremstilling heraf og deres anvendelse som lægemidler | |
| MA26983A1 (fr) | Derives biaryliques de nicotinamide utiles comme inhibiteurs d'iso-enzymes pde4 | |
| PL247096A1 (en) | Agent for fighting against and/or preventing paralyzing effects of microorganisms and method of obtaining new derivatives of n-/2-nitrophenylo/-4-aminopyrimidines | |
| CA2481461A1 (fr) | Derives de n-[phenyl(piperidin-2-yl) methyl] benzamide, leur preparation et leur application en therapeutique | |
| CA2489209A1 (fr) | Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique | |
| WO2005092858A3 (fr) | Composes alpha-aryle ou heteroaryle methyle beta piperidino propanamide en tant qu'antagoniste du recepteur orl1 | |
| MA27573A1 (fr) | Sinomenine et derives de sinomenine, synthese et utilisation. | |
| CA2499822A1 (fr) | Nouveaux derives de pyrimidineamide et leur utilisation | |
| WO2004004730A3 (fr) | Composes pharmaceutiques | |
| MEP11508A (en) | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | |
| MA30767B1 (fr) | Composes azabicycliques en tant qu'inhibiteurs de reabsorption de monoamines | |
| FI971353A0 (fi) | N-(orto-substituoidut bentsyylioksi)imiinijohdannaiset ja niiden käyttö fungisideina, akarisiseina tai insektisideinä | |
| CA2423007A1 (fr) | Composes spiro et inhibiteurs de molecules d'adhesion contenant ces composes comme ingredient actif | |
| CA2422703A1 (fr) | Procede de preparation de mesylates de derives de piperazine | |
| MA29559B1 (fr) | Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique | |
| TW200616954A (en) | N-(1h-indolyl)-1h-indole-2-carboxamide derivatives, their preparation and their application in therapeutics | |
| ATE445619T1 (de) | Pyridinylpyrazolopyrimidinon-derivate als pde 7 inhibitoren | |
| TNSN05321A1 (fr) | Derives de n-pyrrolidine-3-ylamide servant d'inhibiteurs de reabsorption de serotonine et de noradrenaline | |
| TNSN07043A1 (fr) | Oxazolidinones contenant des oxindoles, servant d'agents antibacteriens | |
| UA88925C2 (en) | 4-nitroimidazole derivatives | |
| KR880006239A (ko) | 기라제 억제제, 그의 제조방법 및 용도 |